Qingqing Wang1, Zhigao Dong2, Junnan Su3, Jinmei Huang4, Pingping Xiao5, Lihong Tian6, Yongquan Chen7, Lili Ma8, Xuyan Chen9. 1. Blood Rheumatism Immunology Department, The Second Affiliated Hospital of Xiamen Medical College, Xiamen, Fujian, China. Electronic address: wqq9091@163.com. 2. Blood Rheumatism Immunology Department, The Second Affiliated Hospital of Xiamen Medical College, Xiamen, Fujian, China. Electronic address: dongzhigaozhigao@163.com. 3. Blood Rheumatism Immunology Department, The Second Affiliated Hospital of Xiamen Medical College, Xiamen, Fujian, China. Electronic address: suunchina@163.com. 4. Blood Rheumatism Immunology Department, The Second Affiliated Hospital of Xiamen Medical College, Xiamen, Fujian, China. Electronic address: 710443074@qq.com. 5. Blood Rheumatism Immunology Department, The Second Affiliated Hospital of Xiamen Medical College, Xiamen, Fujian, China. Electronic address: xiaopp0026@163.com. 6. Blood Rheumatism Immunology Department, The Second Affiliated Hospital of Xiamen Medical College, Xiamen, Fujian, China. Electronic address: 846600501@qq.com. 7. Blood Rheumatism Immunology Department, The Second Affiliated Hospital of Xiamen Medical College, Xiamen, Fujian, China. Electronic address: 1992cyq@163.com. 8. Blood Rheumatism Immunology Department, The Second Affiliated Hospital of Xiamen Medical College, Xiamen, Fujian, China. Electronic address: 1183516883@qq.com. 9. Blood Rheumatism Immunology Department, The Second Affiliated Hospital of Xiamen Medical College, Xiamen, Fujian, China. Electronic address: cxy196404@163.com.
Abstract
PURPOSE: Ixazomib is a selective, effective, and reversible inhibitor of 20S proteasome and is approved for the treatment of multiple myeloma. Ubiquitin-conjugating enzyme E2 (UBE2K) is involved in the synthesis of K48-linked ubiquitin chains and is the target of certain drugs used for the treatment of tumors. The purpose of this study was to investigate the relationship between ixazomib and UBE2K in myeloma cells. METHODS: We used CCK-8 and Annexin V-FITC/propidium iodide kit to detect the effects of ixazomib on survival and apoptosis of RPMI-8226 and U-266 myeloma cell lines. Quantitative polymerase chain reaction and western blot were used to detect the change in gene and protein expression levels of myeloma cells treated with ixazomib. Furthermore, the regulatory effects of ixazomib on UBE2K and its downstream targets were investigated following the overexpression of UBE2K. RESULTS: In myeloma cells, ixazomib decreased cell survival and increased apoptosis in a dose-dependent manner. Ixazomib significantly increased the expression of HIST1H2BD, MNAT1, NEK3, and TARS2, while decreasing the expression of HSPA1B and UBE2K. In addition, ixazomib inhibited the proliferation of myeloma cells, blocked cell cycle, induced cell apoptosis, and increased the production of reactive oxygen species by inhibiting UBE2K expression. Lastly, ixazomib regulates mitosis- and apoptosis-related genes by lowering UBE2K expression. CONCLUSION: In summary, ixazomib leads to impaired proliferation of myeloma cells by targeting UBE2K.
PURPOSE:Ixazomib is a selective, effective, and reversible inhibitor of 20S proteasome and is approved for the treatment of multiple myeloma. Ubiquitin-conjugating enzyme E2 (UBE2K) is involved in the synthesis of K48-linked ubiquitin chains and is the target of certain drugs used for the treatment of tumors. The purpose of this study was to investigate the relationship between ixazomib and UBE2K in myeloma cells. METHODS: We used CCK-8 and Annexin V-FITC/propidium iodide kit to detect the effects of ixazomib on survival and apoptosis of RPMI-8226 and U-266myeloma cell lines. Quantitative polymerase chain reaction and western blot were used to detect the change in gene and protein expression levels of myeloma cells treated with ixazomib. Furthermore, the regulatory effects of ixazomib on UBE2K and its downstream targets were investigated following the overexpression of UBE2K. RESULTS: In myeloma cells, ixazomib decreased cell survival and increased apoptosis in a dose-dependent manner. Ixazomib significantly increased the expression of HIST1H2BD, MNAT1, NEK3, and TARS2, while decreasing the expression of HSPA1B and UBE2K. In addition, ixazomib inhibited the proliferation of myeloma cells, blocked cell cycle, induced cell apoptosis, and increased the production of reactive oxygen species by inhibiting UBE2K expression. Lastly, ixazomib regulates mitosis- and apoptosis-related genes by lowering UBE2K expression. CONCLUSION: In summary, ixazomib leads to impaired proliferation of myeloma cells by targeting UBE2K.